Alder Biopharmaceuticals Inc. (ALDR) Jumped On Phase 2 Study Results

Alder Biopharmaceuticals Inc. (ALDR) announced Monday morning that its Phase 2b study of ALD403 met both its primary and secondary efficacy endpoints.

from RTT - Before the Bell http://ift.tt/1pHeOVe
via IFTTT